- Home
- GSIW vs MTVA Comparison
GSIW vs MTVA Comparison
Compare GSIW & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- MTVA
- Stock Information
- Founded
- GSIW 2016
- MTVA 2014
- Country
- GSIW Hong Kong
- MTVA United States
- Employees
- GSIW N/A
- MTVA N/A
- Industry
- GSIW
- MTVA
- Sector
- GSIW
- MTVA
- Exchange
- GSIW Nasdaq
- MTVA NYSE
- Market Cap
- GSIW 8.3M
- MTVA 7.1M
- IPO Year
- GSIW 2023
- MTVA N/A
- Fundamental
- Price
- GSIW $0.44
- MTVA $0.71
- Analyst Decision
- GSIW
- MTVA Strong Buy
- Analyst Count
- GSIW 0
- MTVA 1
- Target Price
- GSIW N/A
- MTVA $12.00
- AVG Volume (30 Days)
- GSIW 45.1K
- MTVA 1.5M
- Earning Date
- GSIW 12-31-2024
- MTVA 05-20-2025
- Dividend Yield
- GSIW N/A
- MTVA N/A
- EPS Growth
- GSIW N/A
- MTVA N/A
- EPS
- GSIW N/A
- MTVA N/A
- Revenue
- GSIW $1,313,795.00
- MTVA N/A
- Revenue This Year
- GSIW N/A
- MTVA N/A
- Revenue Next Year
- GSIW N/A
- MTVA N/A
- P/E Ratio
- GSIW N/A
- MTVA N/A
- Revenue Growth
- GSIW N/A
- MTVA N/A
- 52 Week Low
- GSIW $0.35
- MTVA $0.71
- 52 Week High
- GSIW $12.30
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- GSIW 52.90
- MTVA N/A
- Support Level
- GSIW $0.38
- MTVA N/A
- Resistance Level
- GSIW $0.44
- MTVA N/A
- Average True Range (ATR)
- GSIW 0.03
- MTVA 0.00
- MACD
- GSIW 0.01
- MTVA 0.00
- Stochastic Oscillator
- GSIW 85.11
- MTVA 0.00
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.